BioCryst Pharma

Q2 FY2026 EarningsQ2 FY26 significantly beat consensus across all key financial metrics, driven by a substantial $55.7M revenue recognition from a European licensing deal. Revenue of $218.3M outperformed the $183.3M expectation, while GAAP EPS of $0.30 crushed the $0.1189 mean estimate. Management raised FY26 total revenue guidance to $690M–$715M (vs. $635M–$660M previously) and improved OpEx guidance, signaling enhanced profitability and commercial momentum for ORLADEYO.